| First Author | Bozadjieva-Kramer N | Year | 2021 |
| Journal | Nat Commun | Volume | 12 |
| Issue | 1 | Pages | 4768 |
| PubMed ID | 34362888 | Mgi Jnum | J:344775 |
| Mgi Id | MGI:6753918 | Doi | 10.1038/s41467-021-24914-y |
| Citation | Bozadjieva-Kramer N, et al. (2021) Intestinal-derived FGF15 protects against deleterious effects of vertical sleeve gastrectomy in mice. Nat Commun 12(1):4768 |
| abstractText | Bariatric surgeries such as the Vertical Sleeve Gastrectomy (VSG) are invasive but provide the most effective improvements in obesity and Type 2 diabetes. We hypothesized a potential role for the gut hormone Fibroblast-Growth Factor 15/19 which is increased after VSG and pharmacologically can improve energy homeostasis and glucose handling. We generated intestinal-specific FGF15 knockout (FGF15(INT-KO)) mice which were maintained on high-fat diet. FGF15(INT-KO) mice lost more weight after VSG as a result of increased lean tissue loss. FGF15(INT-KO) mice also lost more bone density and bone marrow adipose tissue after VSG. The effect of VSG to improve glucose tolerance was also absent in FGF15(INT-KO). VSG resulted in increased plasma bile acid levels but were considerably higher in VSG-FGF15(INT-KO) mice. These data point to an important role after VSG for intestinal FGF15 to protect the organism from deleterious effects of VSG potentially by limiting the increase in circulating bile acids. |
